Clinical trials: Heart Transplant Recipient
High Blood Pressure, Liver Transplant
Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)
Liver transplantation is a high risk, high-cost intervention that extends life in over 8,000 patients in the US each year. Of those that receive transplants, 1 in 3 will have a complication related to their heart after…
- Conditions
- High Blood Pressure, Liver Transplant, Renal Function Abnormal
- Trial name
- NCT05275907
- Testing
- Amlodipine Besylate, Chlorthalidone
- Where
- United States
- Sponsor
- Northwestern University
Heart Transplant Infection, Kidney Transplant Infection
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
CMV infection and disease remain a significant clinical challenge for pediatric solid organ transplant (SOT) recipients. Current prevention strategies are limited to prophylaxis in which antiviral medication is administered for a…
- Conditions
- Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
- Trial name
- NCT03924219
- Testing
- CMV T cell Immunity Assay
- Where
- 12 sites in United States
- Volunteers
- 161 people
- Sponsor
- Vanderbilt University Medical Center
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Heart Transplantation
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
The study is designed to evaluate whether Neoral dose optimization together with a therapeutic drug monitoring of Certican will prevent renal dysfunction as observed in the pivotal cardiac trial while maintaining the efficacy.
- Trial name
- NCT00098007
- Testing
- Everolimus (Certican)
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Allograft Vasculopathy
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Many patients with end-stage heart failure, a condition in which the heart fails to pump enough blood to support the body's other organs, are fortunate enough to receive a heart transplant.
- Trial name
- NCT05373108
- Testing
- Macitentan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
Heart Transplantation
L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function
exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal…
- Trial name
- NCT00213915
- Testing
- 12 g of L-arginine glutamate during 6 weeks twice a day
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Heart Transplantation
Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients
Heart transplant recipients do not have nerves to their hearts. This protocol tests the hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in heart transplant recipients compared to healthy…
- Trial name
- P1A4D (NCT00780377)
- Testing
- Bradykinin
- Where
- United States
- Sponsor
- Vanderbilt University
Liver Transplant
Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.
The stress of orthotopic living donor liver transplantation in patients with cirrhosis could induce worsening of an already recorded myocardial dysfunction or may be associated with a new myocardial dysfunction in patients…
- Trial name
- NCT01840514
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Lung Transplant
CIS001 Extension Study of Cyclosporine Inhalation Solution
This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.
- Trial name
- CIS002 (NCT00938236)
- Testing
- Cyclosporine Inhalation Solution (CIS)
- Where
- 16 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- APT Pharmaceuticals, Inc.
Kidney Transplantation
Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.
The main objective of this research is to evaluate the effect, for 36 weeks, of eplerenone on abnormalities observed on cardiac ultrasound in patients with kidney transplantation for at least one year, under cyclosporine or…
- Trial name
- KT-CANOPY (NCT07828223)
- Testing
- Eplerenone
- Where
- 3 sites in France
- Volunteers
- 132 people
- Sponsor
- Central Hospital, Nancy, France
Heart Transplant, Periodontitis
Effect of Non-Surgical Periodontal Therapy on Inflammation in Heart Transplant Recipients
Heart transplant recipients frequently exhibit chronic low-grade systemic inflammation, which can contribute to allograft dysfunction and cardiovascular complications.
- Conditions
- Heart Transplant, Periodontitis, Gingivitis, Systemic Inflammation
- Trial name
- NCT07791927
- Testing
- Full-mouth periodontal debridement
- Volunteers
- 20 people
- Sponsor
- Baskent University
Disorder Related to Cardiac Transplantation
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
This study investigated whether initiation of everolimus together with reduction of calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal impairment would improve renal function.
- Trial name
- NOCTET (NCT00377962)
- Testing
- Everolimus, Mycophenolic acid (MPA)/azathioprine (AZA), Calcineurin inhibitors (CNI)
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 282 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplant Rejection, Heart Transplant Infection
TTV Viral Load in Heart Transplant Recipients
This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation.
- Conditions
- Heart Transplant Rejection, Heart Transplant Infection, Virus
- Trial name
- TTVCoeur (NCT05064462)
- Testing
- Collection of EDTA blood sample (5 to 7 ml)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Transplantation, End-stage Heart Failure
Donor Circadian Rhythm and Its Correlation With Prognosis After Heart Transplantation
The goal of this observational study is to learn about the impact of donor heart procurement time based on circadian rhythm on the long-term outcomes of heart transplant recipients.
- Conditions
- Heart Transplantation, End-stage Heart Failure, Circadian Rhythm
- Trial name
- CIRCA-HTx (NCT07301788)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Diabetes Mellitus Nos New Onset, Hypertrophy, Left Ventricular
New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation
New-onset diabetes (NODAT) after solid organ transplantation is an important clinical challenge associated to increased risk of cardiovascular (CV) events.
- Conditions
- Diabetes Mellitus Nos New Onset, Hypertrophy, Left Ventricular, Vascular Stiffness
- Trial name
- NCT01976689
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people
- Sponsor
- Baskent University
Transplant
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00436384
- Testing
- Monitoring-blood samples drawn for CMV testing
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Gastrointestinal Symptoms, Heart Transplantation
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection.
- Trial name
- NCT00574197
- Testing
- Mycophenolate Sodium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Dysphagia, Heart Transplant Recipients
Respiratory Strength Training in Heart Transplant Recipients
This research study is investigating whether completing breathing exercises before surgery helps heart transplant patients recover after surgery.
- Trial name
- NCT06190171
- Testing
- Active respiratory muscle strength training
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vanderbilt University Medical Center
Heart Transplantation, Acute Renal Failure
Metabolic Pattern of Cyclosporine A and Acute Renal Failure
Following heart transplantation many patients develop acute renal failure in the early posttransplant phase and some are in need of renal replacement therapy for shorter or longer time.
- Trial name
- NCT00264355
- Testing
- cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
Heart Transplant
Tocilizumab in Cardiac Transplantation
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant.
- Trial name
- NCT03644667
- Testing
- tocilizumab, Standard of Care Triple IS
- Where
- 20 sites in United States
- Volunteers
- 385 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)